Biogen Inc. (BIIB)
NASDAQ · Healthcare · Drug Manufacturers - General
Profile
Biogen Inc.
- Exchange
- NASDAQ
- Ticker
- BIIB
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Key facts
Biogen Inc.: key facts
- Biogen Inc. (NASDAQ: BIIB) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Biogen Inc. reported revenue of $9.8B and net income of $1.3B.
- Revenue fell 2.8% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $10.3B and net income was $348.0M.
MonkScore
Biogen Inc.'s MonkScore
MonkScore
MonkScore range: 50–60
as of October 2026
Sector rank: 352 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth10–20
- Profitability30–40
- Quality70–80
- Market Conviction70–80
- Safety60–70
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Biogen Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $10.3B | $9.8B | $9.7B | $9.8B | $10.2B | $11.0B |
| Gross profit | $7.2B | $6.9B | $7.4B | $7.3B | $7.9B | $8.9B |
| Operating income | $786.9M | $1.9B | $2.5B | $2.1B | $2.9B | $2.8B |
| Net income | $348.0M | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B |
| Operating cash flow | $2.2B | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B |
| Capital expenditure | $95.6M | -$153.8M | -$359.8M | -$311.4M | -$240.3M | -$258.1M |
| Free cash flow | $2.3B | $2.1B | $2.5B | $1.2B | $1.1B | $3.4B |
| Total debt | $7.8B | $6.9B | $6.6B | $7.3B | $6.6B | $7.6B |
| Cash | $1.3B | $3.0B | $2.4B | $1.0B | $3.4B | $2.3B |
Revenue growth a year
- 1-year
- 1.4%
- 3-year
- -1.2%
- 4-year
- -2.8%
Compound growth between fiscal years.
Peers
Similar companies
- Merck & Co., Inc.NYSE:MRKMonkScore range: 60–70
- Organon & Co.NYSE:OGNMonkScore range: 60–70
- Johnson & JohnsonNYSE:JNJMonkScore range: 70–80
- Bristol-Myers Squibb CompanyNYSE:BMYMonkScore range: 80–90
- Amgen Inc.NASDAQ:AMGNMonkScore range: 90–100
- AbbVie Inc.NYSE:ABBVMonkScore range: 90–100
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
- Eli Lilly and CompanyNYSE:LLYMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.